Can Multiple Sclerosis be Managed Over a Lifetime? A Rare 72‐Year Journey of Pediatric‐Onset to Secondary Progressive Multiple Sclerosis Authors: Masoud Etemadifar, Ahmadreza Dehghani, Mahdi Rahimi, Amirhossein Ghandehari, Mehri Salari Published: 2026 ABSTRACT ABSTRACTMultiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system characterized by cumulative neurological disability over time. Median survival from symptom onset in large cohort studies is approximately four decades, although substantially prolonged disease courses are uncommon. Pediatric‐onset MS (POMS), defined by symptom onset before age 18, accounts for 3%–5% of cases and may follow a prolonged but ultimately progressive trajectory. We report the case of an 83‐year‐old Iranian woman with an approximately 72‐year history of MS, representing an exceptionally prolonged disease course. Her initial symptom, bilateral optic neuritis, occurred at age 11. She experienced recurrent relapses, including paraplegia and multifocal neurological deficits, before establishing care at our facility at age 55. At that time, diagnostic evaluation included brain magnetic resonance imaging (MRI), visual evoked potentials, cerebrospinal fluid analysis, and laboratory investigations to exclude infectious and autoimmune etiologies. MRI demonstrated periventricular and callosal hyperintense lesions on T2‐weighted sequences with associated cerebral atrophy, consistent with long‐standing demyelinating disease. Neuromyelitis optica spectrum disorder and MOG antibody‐associated disease were excluded. Immunosuppressive therapy with azathioprine was initiated at age 56 and continued for 5 years. By age 58, her disease course evolved into secondary progressive MS (SPMS). Following this transition, management focused on symptomatic treatment, including baclofen for spasticity and long‐term physiotherapy and rehabilitation. Despite severe disability (Expanded Disability Status Scale 6.5) and lower‐limb paralysis, she has remained clinically stable under multidisciplinary follow‐up for nearly three decades. This case represents one of the longest documented MS disease durations and highlights the marked heterogeneity of long‐term outcomes in POMS transitioning to SPMS. Sustained multidisciplinary care, appropriate immunosuppressive therapy, and structured supportive management may contribute to extended survival and preserved quality of life even in advanced disease. Introduction Multiple sclerosis (MS) is considered to be a chronic, long‐standing central nervous system (CNS) disorder, leading to cumulative neurological disability over time [1]. Most patients initially present with relapsing–remitting MS (RRMS) in their adulthood. RRMS is characterized by episodes of neurological relapses followed by periods of recovery [2]. It typically takes 10–20 years for these patients to transition into secondary progressive MS (SPMS), a later type of MS that usually occurs when patients are 50–60 years old [3]. SPMS features a gradual worsening of symptoms independent of relapses, leading to a more challenging disease experience [4]. While MS is considered a lifelong disease, the total duration of the disease from onset to advanced disability rarely exceeds 30 years [5]. About 3%–5% of patients with MS experience their first symptoms of the disease when they are under the age of 18. This type is mostly referred to as pediatric‐onset MS (POMS) [6]. It is often associated with more frequent relapses but slower long‐term progression [7]. It is of great importance to note that the transition of POMS into SPMS later in life is rare and generally takes longer to progress into SPMS compared to adult‐onset MS [8]. Here, we report the case of an 83‐year‐old female from Isfahan, Iran, with a prolonged history of MS. She suffered from bilateral optic neuritis at the age of 11, indicating her first symptom and suggesting a possible POMS patient. Her disease later progressed into SPMS at the age of 58, making for a 72‐year history of MS. Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) were excluded along the patient's journey. Despite longstanding severe disability (Expanded Disability Status Scale [EDSS] > 6), she has remained alive and clinically stable for over two decades under our follow‐up. This case represents one of the longest‐documented disease durations in MS and offers a unique opportunity to explore the long‐term trajectory of POMS transitioning into SPMS, with implications for prognosis and long‐term care in similar patients. Case History and Examination During the first visit to our clinic (age 55), the patient reported a history of vision loss accompanied by bilateral optic neuritis at the age of 11. She recalled experiencing paraplegia around the age of 25. Between the ages of 25 and 55, she intermittently experienced fatigue, scattered paresthesia, and mild urinary incontinence. At age 55, her symptoms included fecal incontinence and lower limb paresthesia. The initial examination revealed a significant decrease in visual evoked potentials (VEP: 196 and 182.2 ms). A lumbar puncture was conducted. The results of the cerebrospinal fluid analysis showed no clinically significant infectious etiologies. Since then, she has had a progressive decline in motor and sensory function. Between ages 56 and 57, she suffered multiple severe relapses, including left facial paralysis, agitation, depression, and ataxia. Urinary and fecal incontinence worsened, and she developed severe paraplegia, becoming bedridden and homebound. At age 72, laboratory tests were obtained. Aquaporin‐4 Immunoglobulin G (AQP4‐IgG) and Myelin Oligodendrocyte Glycoprotein Immunoglobulin G (MOG‐IgG) antibody tests were negative. At age 56, the patient was initiated on immunosuppressive therapy with azathioprine (AZT), which was continued for 5 years until the age of 61. Despite treatment, her disease gradually evolved toward a secondary progressive phenotype. Following this transition, disease‐modifying therapy was discontinued due to the absence of clear inflammatory relapses and the predominantly progressive nature of her clinical decline. Thereafter, management focused on supportive care, including structured physiotherapy and rehabilitation programs aimed at preserving residual motor function and preventing complications of immobility. Baclofen was prescribed for the management of spasticity, with partial symptomatic benefit. At the most recent visit (age 83), her Expanded Disability Status Scale (EDSS) was 6.5, with significant weakness in the left upper limb and complete paralysis of the lower limbs. Figure 1 shows her journey with MS along these years. Daily responsibilities are managed by her family and medical caregivers. Brain MRI prior to this visit demonstrated periventricular hypointense lesions on T1, hypointense lesions along the corpus callosum with brain atrophy on T2 FLAIR (Fluid‐attenuated inversion recovery) sagittal sequences, and worsening periventricular lesions with further atrophy on T2 FLAIR transverse images, consistent with long‐standing MS and SPMS (Figure 2). The timeline chart of the case presentation. AQP4‐IgG, Aquaporin‐4 Immunoglobulin G; EDSS, Expanded Disability Status Scale; MOGAD, Myelin Oligodendrocyte Glycoprotein Antibody Disease; MOG‐IgG, Myelin Oligodendrocyte Glycoprotein Immunoglobulin G; NMOSD, Neuromyelitis Optica Spectrum Disorder; POMS, Pediatric‐Onset Multiple Sclerosis; SPMS, Secondary Progressive Multiple Sclerosis; VEP, Visual Evoked Potential. (A) (Axial T1 MRI imaging) shows hypointense lesions in the periventricular area, highlighting the older demyelinating lesions due to long‐standing MS. (B, C) (Sagittal T2 MRI imaging) show hyperintense lesions showing severe atrophy of the corpus callosum. (D–F) (Axial T2 FLAIR* MRI imaging) show cumulative periventricular lesions. Further brain atrophy is also seen in these images, consistent with SPMS. *Flair, Fluid‐attenuated inversion recovery. Differential Diagnosis Multiple sclerosis (MS) is supported by the bilateral optic neuritis in her childhood, subsequent multifocal neurological relapses clinically presented as paraplegia, facial paralysis, and ataxia, then abnormal visual evoked potentials, and a progressive decline in function over decades further strengthen the definite diagnosis of MS. The brain MRI demonstrating periventricular and callosal lesions with cerebral atrophy aligns with long‐standing demyelinating plaques and a secondary progressive trajectory. Neuromyelitis optica spectrum disorder (NMOSD) was considered because of severe early optic neuritis and later sphincter dysfunction. However, aquaporin‐4 IgG testing was negative. In addition, the imaging pattern in this case emphasizes periventricular and callosal involvement rather than the typical NMOSD manifestation for optic nerves and longitudinal spinal cord lesions, making NMOSD less likely in the context of the available data. Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) was also considered because of the history of optic neuritis and relapses. Testing for MOG‐IgG was negative. The very gradual evolution to a secondary progressive course and the prominent periventricular/callosal lesion burden are also atypical for MOGAD, which more commonly follows a relapsing–remitting pattern without steady progression between attacks. Hence, the diagnosis of MOGAD was rejected. In addition to demyelinating disorders, alternative etiologies were systematically evaluated. Autoimmune vasculitis was excluded through appropriate serologic testing, including inflammatory markers and autoimmune panels, which were unremarkable. Infectious causes of chronic or relapsing neurological dysfunction were also ruled out through relevant laboratory investigations. The absence of systemic features, negative laboratory findings, and the characteristic radiologic pattern further supported the diagnosis of multiple sclerosis. Conclusion and Results MS was initially diagnosed at age 55, with the disease course later classified as pediatric‐onset MS based on symptom onset at age 11. At age 58, secondary progressive multiple sclerosis (SPMS) was suggested, with an EDSS of 4.0 and > 6 months without relapses. She has since lived approximately 25 years with SPMS. Over the 28 years under our follow‐up, she has maintained clinical stability despite severe disability, attributed to regular healthcare visits, palliative care, and strong family support. In recent years, her EDSS progressed to 6.5; she remains bedridden with full lower‐limb paralysis and requires 24‐h assistance. This case represents a rare, prolonged disease duration of approximately 72 years, illustrating that sustained multidisciplinary care and family support can contribute to a reasonable quality of life despite advanced disability. Discussion MS is known to be one of the most common chronic diseases of the CNS. It often leads to severe disability and the need for tertiary care and a lot of support from the patients' family and loved ones over time, especially in those with long‐standing disease [9, 10]. Most studies suggest that the average duration of MS, from onset to severe disability or death, ranges from 30 to 40 years [11, 12]. In this study, we presented an extremely rare case of an 83‐year‐old Iranian female with a disease duration of approximately 72 years. A journey of a lifelong disease affecting every aspect of the patient's life. This patient had her first symptoms at the age of 11, which indicates the POMS type of the disease. POMS accounts for only 3%–5% of all MS cases globally. Compared to adult‐onset MS, POMS is known to have more relapses early in the disease, but the progression to severe disability is usually slower [13]. This may be because the brain tissue of relatively young patients has more plasticity and the ability to recover better after relapses [14]. However, most POMS patients still develop disability over time, especially after transitioning to SPMS if that happens [15]. In our case, the patient entered the SPMS phase around the age of 58, which is fairly similar to the median age of the diagnosis of SPMS reported before [16]. Since then, she has lived with SPMS for about 25 years. Her current Expanded Disability Status Scale (EDSS) score is 6.5, and she is bedridden with full lower limb paralysis. Despite this severe disability, her survival for almost three decades in the SPMS phase is notable. The reasons for this extended survival are not fully clear, but several factors may have played a role. This lifelong survival with MS could be due to the possible role of immunological or protective genetic factors that can inhibit the progression of the disease [17]. Environmental factors might play a major role in slowing down the transition of MS into worse types like SPMS [18]. Due to easier access to medical healthcare services and living in Isfahan, an area with a higher quality of healthcare and higher prevalence of MS in Iran, this may have contributed to earlier awareness of the disease and better long‐term medical care [19]. Her strong family support and high socioeconomic status aided her long‐term survival with MS despite the lower chance of living with MS under her disease conditions [20]. All of these made her regular and consistent access to medical healthcare services possible, something not usual in her area. Another important point is that she did not have frequent relapses after entering the SPMS phase. This gradual disease course, without many acute episodes, may have limited complications such as severe infections or hospitalizations. However, the long duration of MS still led to several complications. She suffered from urinary and fecal incontinence, recurrent fatigue, and eventually paraplegia. These symptoms greatly affected her quality of life and required full‐time care. Because her early symptoms started decades before modern diagnostic tools were available, there may have been delays or inaccuracies in diagnosis. MRI, which is now essential in diagnosing MS, was not available at that time [21]. The patient's diagnosis was confirmed only in her mid‐50s, which shows the challenges of diagnosing MS in earlier times. This also raises the possibility of recall bias, since many of her earlier symptoms were reported from memory. Her experience of long‐standing MS also highlights the importance of palliative care in chronic diseases, especially in their progressed form like SPMS [22]. Even before the emergence of disease‐modifying treatments, she received careful symptom management and psychological support from almost everybody involved in her medical care and family. Documenting such rare cases can help improve our understanding of the full range of long‐standing MS outcomes. There were no cases with this long MS duration based on our review of the literature. Long‐term population‐based cohort studies provide important context for interpreting the duration observed in our patient. A 50‐year follow‐up study from Western Norway reported a median survival from symptom onset of approximately 41 years, with women demonstrating longer survival compared to men [11]. Other large‐scale natural history cohorts have similarly reported median disease durations ranging from three to four decades [23, 24]. While these studies indicate that extended survival is possible, reports of disease durations exceeding 60 years remain uncommon in the literature. In this context, the approximately 72‐year disease course observed in our patient places her at the extreme upper range of documented MS trajectories. Although rare, such prolonged survival underscores the heterogeneity of disease progression and highlights that a subset of patients, particularly women with pediatric‐onset disease and gradual transition to secondary progression, may experience remarkably extended disease durations. Recall bias is thought to be the most influential limitation of this case, as the data before our follow‐up were based solely on the memory of the patient and her family. Additionally, spinal MRI was not obtained during follow‐up, which restricts full radiologic characterization of spinal cord lesion burden and limits correlation with her long‐standing motor and sphincter dysfunction. Despite all of these limitations, this report provides valuable insights into the long‐term course of MS. In conclusion, this is one of the longest reported cases of MS in the literature. It shows that some patients, especially those with POMS and slow disease progression, can live for many decades even with long‐term significant disability and that patients can have higher life expectancies with consistent access to medical and palliative care. Author Contributions Masoud Etemadifar: conceptualization, investigation, project administration, supervision, writing – review and editing. Ahmadreza Dehghani: conceptualization, validation, visualization, writing – original draft, writing – review and editing. Mahdi Rahimi: visualization, writing – original draft. Amirhossein Ghandehari: visualization, writing – review and editing. Mehri Salari: supervision, writing – review and editing. Funding The authors have nothing to report. Consent Written informed consent was obtained from the patient for the publication of this study and for using any images needed. Conflicts of Interest The authors declare no conflicts of interest.